Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MMP10 | P09238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411153 | 0.93 | MAPT (0.40) | LIPGMAPTKMT2AMEN1RXFP1 | |
| SCHEMBL2409603 | 0.90 | FEN1 (0.43) | MAPTMAPK8KMT2AMEN1FEN1 | |
| SCHEMBL2414794 | 0.86 | PTGDR2 (0.46) | MAPTMAPK8ALDH1A1FEN1PDE4A | |
| SCHEMBL2409299 | 0.85 | TOP2A (0.49) | LIPGMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL2409528 | 0.85 | MEN1 (0.46) | HSD17B10MAPTMAPK8KMT2AMEN1 | |
| SCHEMBL2409859 | 0.85 | FEN1 (0.42) | MAPTMAPK8KMT2AMEN1ALDH1A1 | |
| SCHEMBL4182610 | 0.81 | ADORA2A (0.43) | MAPTKMT2AMEN1ALDH1A1PSMD14 | |
| SCHEMBL4188055 | 0.80 | MAPT (0.49) | HSD17B10MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL2409456 | 0.79 | PDE1A (0.51) | MAPTMAPK8ALDH1A1FEN1PDE4A | |
| SCHEMBL9043908 | 0.76 | MAPT (0.49) | MAPTKMT2AMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559716-B1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | KANAZAWA HASHIME | 2010-04-15 | — | — | US | disclosed |
| US-7608716-B2 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1559716-A1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | Grelan Pharmaceutical Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | PDE3B, PDE3A, PDE4A | LIPG 3679/4885HSD17B10 903/4885MAPT 4759/4885 |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | PDE3B, PDE3A, PDE4A | LIPG 3798/4885HSD17B10 1006/4885MAPT 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.